Artificial intelligence in cancer target identification and drug discovery

Y You, X Lai, Y Pan, H Zheng, J Vera, S Liu… - … and Targeted Therapy, 2022 - nature.com
Artificial intelligence is an advanced method to identify novel anticancer targets and discover
novel drugs from biology networks because the networks can effectively preserve and …

Systems biology based drug repositioning for development of cancer therapy

B Turanli, O Altay, J Borén, H Turkez, J Nielsen… - Seminars in cancer …, 2021 - Elsevier
Drug repositioning is a powerful method that can assists the conventional drug discovery
process by using existing drugs for treatment of a disease rather than its original indication …

Potential biomarkers and therapeutic targets in cervical cancer: Insights from the meta-analysis of transcriptomics data within network biomedicine perspective

M Kori, K Yalcin Arga - PLoS One, 2018 - journals.plos.org
The malignant neoplasm of the cervix, cervical cancer, has effects on the reproductive tract.
Although infection with oncogenic human papillomavirus is essential for cervical cancer …

[图书][B] A Meta-Analysis of Cancer Immunotherapy: Evaluating Efficacy, Predictive Biomarkers, and Therapeutic Resistance

N Tzenios - 2022 - search.proquest.com
This dissertation traces the historical trajectory of cancer immunotherapy, beginning with
early attempts at vaccination in ancient civilizations to the development of monoclonal …

Identification of prognostic biomarker signatures and candidate drugs in colorectal cancer: insights from systems biology analysis

MR Rahman, T Islam, E Gov, B Turanli, G Gulfidan… - Medicina, 2019 - mdpi.com
Background and objectives: Colorectal cancer (CRC) is the second most common cause of
cancer-related death in the world, but early diagnosis ameliorates the survival of CRC. This …

The identification of essential cellular genes is critical for validating drug targets

T Xu, S Wang, T Ma, Y Dong, CR Ashby Jr, GF Hao - Drug Discovery Today, 2024 - Elsevier
Highlights•The identification of novel drug targets is a key step in drug innovation.•Essential
genes are vital for organism survival and are promising drug targets.•We describe in detail …

Drug targeting and biomarkers in head and neck cancers: insights from systems biology analyses

T Islam, R Rahman, E Gov, B Turanli… - Omics: a journal of …, 2018 - liebertpub.com
The head and neck squamous cell carcinoma (HNSCC) is one of the most common cancers
in the world, but robust biomarkers and diagnostics are still not available. This study …

Potential signature therapeutic biomarkers TOP2A, MAD2L1, and CDK1 in colorectal cancer: a systems biomedicine-based approach

P Priyamvada, S Ramaiah - Biochemical Genetics, 2024 - Springer
Colorectal cancer is the third deadliest and fourth most diagnosed cancer. It is
heterogeneously driven by varied mutations and mutagens, and thus, it is challenging for …

miRNA-based signature associated with tumor mutational burden in colon adenocarcinoma

W Xue, Y Wang, Y Xie, C Yang, Z Gong, C Guan… - Frontiers in …, 2021 - frontiersin.org
Colon adenocarcinoma (COAD) is one of the most common malignant tumors. Tumor
mutation burden (TMB) has become an independent biomarker for predicting the response …

[HTML][HTML] Circular RNA complement factor H (CFH) promotes glioma progression by sponging miR-149 and regulating AKT1

A Bian, Y Wang, J Liu, X Wang, D Liu… - … medical journal of …, 2018 - ncbi.nlm.nih.gov
Background Circular RNAs (circRNAs) are widely expressed in mammals and can regulate
the development and progression of human tumors. has_circ_0015758 (circ-CFH) is an …